Author: Vivian Xie 2nd July 2026

In recent years, Asia-Pacific has emerged as the world's fastest-growing pharmaceutical market, projected to reach USD 710.78 billion by 2034. However, with over 4.7 billion inhabitants speaking thousands of languages across upwards of 50 countries, the area’s pharma sector will need to meet myriad regulatory and linguistic demands to deliver packaging and labelling solutions that work for end users across the region.

From smart labelling technologies to combat counterfeiting to pharmaceutical packaging solutions in multiple languages, pharmaceutical companies in the Asia-Pacific have a great deal of options to explore in order to meet these regulatory issues. And with Pharmapack Asia taking place this November at Marina Bay Sands in Singapore, industry leaders have a new event in their calendar to source new solutions and gain insights from the experts at the forefront of packaging innovation.

Addressing Complexity at Scale: The Challenge of Multilingual Labelling

Asia-Pacific's linguistic diversity creates labelling challenges which are unmatched in any other global region. Market analysis expects [1] the Asia-Pacific’s multilingual packaging market to grow more quickly than anywhere else, with the region’s pharmaceutical products incorporating multilingual content to widen their potential customer base while still addressing patient safety.

Precise labels and packaging both guide accurate usage for end users and warn against any potential risks that medication could cause. Improperly translated packaging can lead to critical consequences, so implementing multilingual labelling demonstrates a company's commitment to inclusivity and patient-centred care, developing credibility and trust. Pharmaceutical packaging and labelling are subject to stringent global regulations, with every country maintaining particular guidelines to ensure transparency and clarity in patient communications.

Country-Specific Language Requirements

The Asia-Pacific regulatory landscape mandates diverse language requirements. According to regulatory data, language requirements vary significantly across major markets: China requires all labelling to be in Chinese, whilst Hong Kong accepts English or Chinese. India mandates labelling in English, but often requires additional regional languages depending on the state of distribution. Both Indonesia and Vietnam accept English alongside their own language, while Japan and Korea mandate Japanese and Korean, respectively.

Singapore's Health Sciences Authority provides flexibility by accepting English labelling, positioning Singapore as an attractive entry point for companies seeking regional market access. Thailand's FDA has begun driving digital modernisation through e-labelling initiatives, though recent regulatory updates [2] have demonstrated that the country’s e-labelling system is voluntary and restricted to injectable dosage forms and products for medical facilities that are not sold in pharmacies.

Space Constraints and Information Density

The challenge extends beyond simple translation. Manufacturers serving multiple countries will need to include warnings, instructions, and technical data on their labels, localised into each target market’s lexicon of terminology and grammar. With limited space available to include all of the required information without overloading the design, companies significant balancing act.

Effective pharmaceutical labels must convey a great deal of essential information such as:

• product name (proprietary and non-proprietary) 
• active ingredients and quantities
• dosage form and strength 
• batch number and expiration date 
• storage conditions 
• manufacturer details 
• comprehensive usage instructions

The Smart Labelling Technology Transforming Patient Safety

While multilingual requirements address linguistic accessibility, smart labelling technologies are revolutionising pharmaceutical packaging through digital connectivity, authentication capabilities and features for patient engagement. Industry research demonstrates [3] that smart labels refer to intelligent labelling solutions that incorporate RFID, NFC and QR technologies and sensors to enable real-time data capture, tracking, and interaction across healthcare and pharmaceutical applications.

These labels enhance product authentication, monitor environmental conditions and support serialisation for regulatory compliance. By enabling seamless communication between packaging, digital systems and end users, smart labels improve supply chain transparency, patient safety and inventory management, which explains their widespread adoption in drug packaging, medical devices, biologics and clinical trial logistics.

Asia-Pacific: Leading the Way in Smart Label Adoption

Market intelligence indicates [4] that the Asia-Pacific accounted for the largest global smart labels market share in 2024, driven by growing regulatory scrutiny and reforms introduced to ensure drug safety and supply chain transparency. Regional authorities are implementing policies that boost the integration of track-and-trace technologies within pharmaceutical distribution networks, contributing to accelerated adoption of smart labelling solutions in prescription drug authentication and temperature-sensitive shipments.

The rapid development of healthcare infrastructure, alongside government-backed digital health initiatives across Southeast Asia, is increasing the deployment of smart labels in hospital and retail pharmacy settings. This regional leadership reflects the Asia-Pacific’s dual position as the world's largest pharmaceutical manufacturing hub and its fastest-growing pharma market.

Enabling Patient Engagement With NFC Technology

Near-field communication (NFC) technology represents one of the most promising smart labelling innovations for patient engagement and medication adherence. Research into NFC applications in pharmaceuticals [5] reveals that NFC tags provide three critical features: anti-counterfeiting protection, patient engagement capabilities and automated device integration.

Apps, wearables and detectors all provide an active NFC interface between patients and healthcare professionals; apps give reminders, alarms and medical tips, update medical treatment plans and procedures and encourage patients to engage with their treatment more interactively. This feature has been particularly effective for patients suffering from chronic diseases, high blood pressure, diabetes and other conditions requiring ongoing management of medication.

Smart RFID/NFC label solutions [5] demonstrate practical implementation. NFC labels give patients access to usage instructions, dosage information and digital services, improving their treatment adherence and supporting modern healthcare concepts, while remaining intuitive to use. When customers use NFC-equipped medicines, they become part of cloud-based and IoT functionality; NFC-enabled applications offer one-to-one communication between medical specialists and patients, with specialists using them to check patients' recovery and health conditions, whilst patients follow treatment guides properly and receive dosage reminders. Quick notifications from NFC apps remove patients’ reliance on manual prescriptions, improving their overall engagement and experience.

QR Codes: Accessible Information at Scale

QR codes provide a cost-effective smart labelling solution that delivers enhanced information access without requiring specialised hardware beyond smartphones. Analysis of e-labelling trends [6] shows that QR codes and Unique Device Identifiers (UDIs) are now widely used to link product packaging to up-to-date online information, reflecting a broader push toward traceability, supply chain transparency and improved safety monitoring.

Modern e-labelling systems let companies serve users dynamic content which is tailored to match their language, location and device. This capability proves especially valuable in global markets where paper labels are constrained by space or translation challenges. Recently published research [7] confirms that QR codes have significant potential to improve how patients and healthcare professionals interact with prescribed medications and treatments.

QR codes also enable instant access to comprehensive medication information in patients' preferred languages, overcoming space constraints that previously limited printed multilingual labels. Patients can scan codes to access detailed usage instructions, safety information, potential side effects, and drug interaction warnings, all presented in their desired language regardless of the physical label's limitations.

Protecting Asia-Pacific's Pharmaceutical Supply Chain with Anti-Counterfeiting Labels

Pharmaceutical counterfeiting represents one of the most significant healthcare challenges in the region, with the World Health Organisation estimating that up to 10% of developing countries’ medicines may be counterfeit. This reality drives urgent demand for anti-counterfeiting labels that protect product integrity, ensure patient safety and safeguard brand reputation.

The growing number of counterfeit goods in the pharmaceutical industry represents one of the largest factors driving market growth. [8] Counterfeit drugs, supplements and personal care products pose ethical challenges in terms of both consumer safety and brand integrity, and regulatory bodies are increasing their enforcement of anti-counterfeit measures. As a result, manufacturers are under pressure to implement advanced security solutions, including holograms, serialisation, QR codes and tamper-evident seals.

Pharmaceuticals: The Largest Anti-Counterfeiting Segment

Market intelligence confirms [9] that pharmaceuticals represent the largest market segment for anti-counterfeiting packaging in the Asia-Pacific, driven by the region's growing drug manufacturing base and high levels of counterfeit drugs. The vast majority of pharmaceuticals produced in the region are exported globally, requiring compliance with international track-and-trace standards. Consequently, pharmaceutical companies are increasing their spend on advanced security solutions to protect products, comply with regulations and maintain market access.

The Asia-Pacific is the fastest-growing region in the anti-counterfeit packaging market, expanding at a CAGR of 16%,[10] thanks to rapid growth in e-commerce, industrialisation and stricter regulations. In India, a 2023 government mandate requiring QR codes on pharmaceutical packaging led to a 14% rise in sales of anti-counterfeit solutions in 2024.

Advanced Authentication Technologies

Modern anti-counterfeiting labels incorporate multiple layers of authentication to bolster security for the end user. Pharmaceutical security portfolios [11] demonstrate the range of available solutions, featuring security threads, holograms and off-the-shelf solutions, all specifically designed to counter tampering and counterfeiting.

For advanced protection, designers can incorporate unique components and customised security features into pharmaceutical labels to identify and track products. Tamper-evident solutions provide immediate visual indication that packaging has been compromised, while serialisation enables track-and-trace capabilities throughout the supply chain.

NFC smart label authentication technology [12] demonstrates how advanced solutions combat counterfeiting through real-time authentication. The technology empowers consumers and manufacturers alike, ensuring product authenticity and enhancing supply chain transparency. Patients can instantly verify product authenticity by tapping NFC-enabled labels with their smartphones, providing swift confidence that their medication is the real thing.

Driving Adoption Through Regulatory Mandates

Regulatory requirements are accelerating the adoption of anti-counterfeiting labelling across the Asia-Pacific. Trade regulations such as serialisation mandates [13] and anti-counterfeit label requirements in global pharma trade have influenced adoption, reinforcing market growth momentum. Major players are accelerating technological innovation and expanding global footprints to meet this demand.

There are national mandates from China's drug traceability system, India's track-and-trace system and ASEAN harmonisation efforts to ensure that pharmaceutical packaging supports all serialisation capabilities. Regulations from China's National Medical Products Administration [14] call for all label details to be authenticated through secure systems, including adopted names, storage conditions, production dates, batch numbers, expiry dates, approval numbers and manufacturer information.

Navigating Asia-Pacific's Complex Regulatory Compliance Requirements

Successfully implementing pharmaceutical labelling solutions for Asian markets requires a comprehensive understanding of the region’s diverse regulatory frameworks. Pharmaceutical compliance guidance [15] emphasises that when delivering life-saving medicines, patient safety is always at the centre, and medicines are subject to extremely stringent regulatory and compliance rules. This applies equally to packaging and labelling materials, which are subject to numerous compliance regulations and quality standards including EU Regulation 1935/2004/EC, FDA 175.105, ISO standards, and the Falsified Medicines Directive 2011/62/EU.

Material Safety and Migration Testing

Pharmaceutical labelling materials must meet stringent safety requirements to ensure they do not compromise product quality. Low-migration adhesives prevent chemicals within the labels from interacting with pharmaceutical products, while materials must be able to withstand environmental conditions including cryogenic temperatures for biologics, high temperatures during sterilisation and moisture exposure during storage and distribution.

Drug Master Files (DMFs) provide regulatory authorities with detailed information about labelling materials, adhesives and manufacturing processes, demonstrating compliance with safety and quality requirements. Pharmaceutical companies increasingly require their labelling suppliers to maintain comprehensive documentation, conduct extensive testing and implement robust quality management systems.

Labelling Innovation as Competitive Advantage

As the pharma market in the Asia-Pacific continue their explosive growth, labelling compliance has never been more important, and the Labelling Zone at Pharmapack Asia provides a one-stop shop for the region’s pharma leaders to start constructive conversations with material suppliers, technology providers and service organisations that deliver labelling solutions which meet the unique challenges of the Asia-Pacific pharma market.

Companies that master multilingual packaging requirements with smart labelling technology and robust anti-counterfeiting measures will be better equipped to reach new markets more efficiently, building stronger brand trust and enhancing patient engagement.